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Prognosis of acute myeloid leukemia relies heavily on the cytogenetic and molecular abnormal-
ities. AML1-ETO fusion protein resulting from t(8;21), a recurring cytogenetic abnormality, is
known to be associated with favorable prognosis. Additional molecular defects may, however,
co-operate with the fusion proteins and alter the course of the disease. Among the additional
cytogenetic defects, presence of Philadelphia (Ph) chromosome has rarely been documented in
this subtype. Little is known about the consequences of its interactions with AML1-ETO, and its
effect on morphological and clinical picture. Moreover, Ph+ clones or subclones may appear at
any point during the disease course. We herein report one such unusual case of a 26-year-old
female, who was diagnosed to have t(8;21) and managed accordingly. During disease relapse
after 2.5 years, the bone marrow showed extensive eosinophilia and basophilia. Subsequent
molecular testing showed the presence of BCR-ABL in addition to the AML1-ETO fusion product.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Philadelphia (Ph) chromosome, along with the correspond-
ing BCR-ABL fusion transcript, results from the reciprocal
translocation of the BCR gene on chromosome 22 and thecute mye-
/10.1016/
2 M.K. Singh et al.ABL gene on chromosome 9 and is the hallmark of chronic
myeloid leukemia (CML). Ph+ acute lymphoblastic leukemia
(Ph+ ALL) is another well-established entity, which is known
to be associated with poor prognosis. However, Ph positivity
is rarely seen in acute myeloid leukemia (AML) and accounts
for approximately 1% of all AML [1]. If present in AML, this
mutation can interact with other Class I and II mutations,
and further confer the leukemic cells with abnormal prolif-
erative and antiapoptotic properties [1]. Translocation
(8;21) [t(8;21) AML1-ETO] is one such Class II mutation,
which is reportedly the most common recurrent cytogenetic
abnormality in AML. It is found to be associated with other
cytogenetic abnormalities such as del Y and del 9q(22) [2].
Although the co-existence of inv(16) and t(9;22) has been
reported in both de novo AML and myeloid blast crisis in
CML, concurrence of BCR-ABL1 and t(8;21) is extremely rare
[1]. So far, its impact on morphology and clinical picture is
not well-described in the literature. We document here an
interesting case of AML1-ETO-positive AML where both
BCR-ABL and AML1-ETO fusion transcripts were detected
simultaneously at the time of relapse. The study was
approved by the Institutional Review Board.
Case report
A 26-year-old female, diagnosed and treated as a case of
AML, presented 2.5 years later with increasing leucocyte
count. At the time of initial presentation in 2012, her con-
ventional cytogenetic analysis had shown a normal female
karyotype. However, molecular analysis revealed the pres-
ence of AML1-ETO fusion transcript. FLT3-ITD and nucle-
ophosmin 1 (NPM 1) mutations were not detected. She
had received the standard 3 + 7 induction treatment proto-
col for AML. The bone marrow of the patient showed mor-
phological remission after completion of induction
therapy. Following induction therapy she received four
cycles of consolidation therapy with high-dose cytarabine.
The consolidation phase was uneventful and the patient
remained in remission until March 2015. In her present
follow-up, the total leucocyte count was elevated andFigure 1 Photomicrographs. (A) May-Gru¨nwald–Giemsa-stained b
eosinophils and basophils in adjunct to blasts (arrows); (B) agarose
products of second-round nested PCR: p210 (b2a2) fusion product in
(8;21) in Lane 4; negative and positive controls of p190 product
PC = positive control.
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marrow examination confirmed the presence of disease
relapse. Differential count on aspiration smear showed
approximately 30% blasts, 50% eosinophils including eosino-
phil and basophil (Eo-Baso) precursors, and 5% basophils
(Figure 1), which were not present in the original marrow.
Such extensive eosinophilia and basophilia prompted us to
look for other additional molecular abnormalities like Ph
chromosome. Nested polymerase chain reaction (PCR) as
well as quantitative real-time PCR showed the presence of
p210 fusion transcript. Patient was again given a similar 3
+ 7 protocol of daunorubicin and cytarabine, respectively.
Interestingly, she achieved morphological remission. Ima-
tinib was not added to the treatment protocol because of
low copy numbers of the clone. Further, she has been
planned for allogenic bone marrow stem cell
transplantation.
Discussion
AML with t(8;21)(q22;q22)/RUNX1-RUNX1T1 (AML1-ETO)
belongs to the subgroup of AMLs with recurrent cytogenetic
abnormalities and is found in about 7% of de novo adult AMLs
[3]. However, the core binding factor (CBF)-related fusion
proteins and inv(16) alone are incapable of promoting leuke-
mic transformation. Certain secondary alterations cooper-
ate with CBF fusion proteins in leukemogenesis, which
encode protein effectors controlling cell proliferation and
confer survival advantage to the malignant cells (Class I
mutations) [4]. These Class I mutations commonly include
mutations in the FLT3, RAS, KIT, and JAK2 genes. Almost
90% of AML with t(8;21) harbor additional secondary chro-
mosome aberrations/mutations including FLT3, KIT, and
RAS [5]. Although CBF-related AML confers favorable prog-
nosis [2], a significant proportion of patients with CBF-AML
still relapse at different points of time, indicating the need
to identify other mutations that may be interplaying in such
patients. Ph+ AML, by contrast, constitutes <1% of newly
diagnosed AML cases and is considered to have an adverse
prognosis [6–8]. BCR-ABL1 mutation behaves as a Class Ione marrow aspiration smear showing the presence of numerous
gel electrophoresis showing polymerase chain reaction (PCR)
Lane 2; AML1-ETO fusion product in Lane 3; positive control for t
in Lanes 1 and 5, respectively; 50-bp ladder in Lane 6. Note.
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Co-existence of AML1-ETO and BCR-ABL1 transcripts 3mutation, as it confers the cells abnormal proliferative
capacity. However, co-occurrence of the BCR-ABL1 fusion
transcript along with other recurring cytogenetic abnormal-
ities in AML is extremely rare [1,6,9–11] and even rarer is
the acquisition of this mutation during relapse of CBF-AML
[1].
In a retrospective study of >1000 AML cases, Bacher et al.
[1] reported only five cases with recurrent cytogenetic
abnormality co-existing with Ph+ subclones. These recur-
rent abnormalities included two cases of t(8;21)/RUNX1-
RUNX1T1; one patient each with inv(16)/CBFB-MYH11,
NPM 1 mutation, and secondary AML following myelodys-
plastic syndrome (MDS) with 5q deletion. These patients
developed Ph chromosome at different periods [1]. Simi-
larly, Soupir et al. [12] reported only four cases of sec-
ondary AML, all of whom developed t(9;22) following
treatment for pre-existing AML or MDS over the study period
of 8 years. Chen et al. [13] reported Ph positivity in one of
their AML patients at the time of relapse and proposed that
the Ph chromosome was a secondary aberration, which pos-
sibly had a role in clonal evolution and disease progression.
Although many studies have reported the presence of
t(9;22)/BCR-ABL1 at the time of initial diagnosis in cases
of different subtypes of AML [7,8,10–12], its concurrence
in relapsed AML patients with favorable cytogenetics group,
that is, t(8;21)/inv(16), is rare. Our patient did not have any
of the other established risk factors associated with relapse
in AML patients such as older age, adverse cytogenetics or
FLT3 mutation, or shorter duration of first remission (CR1)
[14]; yet, she relapsed. Although it may be difficult to
conclude whether these subclones were present at diagnosis
or developed during relapse, the authors believe that these
Ph+ clones evolved during relapse, because the patient had
achieved remission initially.
In comparison with ALL, status of BCR/ABL1 at the time
of diagnosis or relapse in AML patients is a gray zone of this
malignancy. Whether it is a co-incidental finding or has
implications on the overall clinical picture is not yet vali-
dated. The role of incorporating imatinib in treatment is
also not well-known in such patients. Different authors
had published their experiences with imatinib and the med-
ian response duration ranges from 2.5 months to 15 months
[14]. A larger number of patients and in vitro studies need
to be taken up to ascertain whether this mutation is just a
component of the genetic instability or actually confers a
higher proliferative potential to the leukemic cells.
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